Fluicell

Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening. With the groundbreaking Nexocyte platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues. Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicells first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients. Nexocyte-generated tissues also enable our world-leading partners to advance their drug-screening capabilities...

Biotechnology,bioprinting,microfluidics,biomedicine,single-cell biology,single-cell pharmacology,regenerative medicine,diabetes,and cell therapy

Fluicell operates in the Biotechnology research industry.

Fluicell's revenue is 1b+

Fluicell has 11 - 50 employees.